A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting now Phase 3 NCT07258511
Run by Janssen Research & Development, LLC · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Who can join (things the study team will check)
Inclusion: * Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: 1. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria 2. Measurable disease at screening as assessed by central laboratory * Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody * Documented evidence of progressive disease (PD) or failure to achieve a response (that is partial response \[PR\] or better) to the last line of therapy based on investigator's determination of response by IMWG criteria * Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration Exclusion: * Active hepatitis of infectious origin * Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM * Suspected or known allergies, hypersensitivity, or intoler…
Where this trial is running
- UAMS, Little Rock, Arkansas, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California San Francisco, San Francisco, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
- Moffit Cancer center, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
- Mission Cancer Blood, Waukee, Iowa, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
+ 91 more sites.
Who to contact
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07258511.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.